{'52WeekChange': 0.6146709,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Washington Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 36.59,
 'askSize': 800,
 'averageDailyVolume10Day': 131950,
 'averageVolume': 204098,
 'averageVolume10days': 131950,
 'beta': None,
 'beta3Year': None,
 'bid': 36.57,
 'bidSize': 800,
 'bookValue': 7.802,
 'category': None,
 'circulatingSupply': None,
 'city': 'Stamford',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 37.46,
 'dayLow': 36.04,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -19.87,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1260528256,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 40.965714,
 'fiftyTwoWeekHigh': 49.79,
 'fiftyTwoWeekLow': 17.02,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 15701840,
 'forwardEps': -1.63,
 'forwardPE': -22.41718,
 'fromCurrency': None,
 'fullTimeEmployees': 60,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.15584,
 'heldPercentInstitutions': 0.76443,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/springworkstx.com',
 'longBusinessSummary': 'SpringWorks Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, acquires, develops, and '
                        'commercializes medicines for underserved patient '
                        'populations suffering from rare diseases and cancer. '
                        'Its lead product candidate is nirogacestat, an oral '
                        'small molecule gamma secretase inhibitor that is in '
                        'Phase III clinical trial for the treatment of desmoid '
                        'tumors. The company is also developing mirdametinib, '
                        'an oral small molecule MEK inhibitor that is in Phase '
                        'IIb clinical trial for the treatment of '
                        'neurofibromatosis type 1-associated plexiform '
                        'neurofibromas; Nirogacestat + belantamab mafodotin, '
                        'which is in Phase Ib clinical trial for the treatment '
                        'of relapsed or refractory multiple myeloma (RRMM); '
                        'and Nirogacestat + ALLO-715 that is in preclinical '
                        'trials for the treatment of RRMM. In addition, it is '
                        'developing Mirdametinib + lifirafenib, a combination '
                        'therapy that is in Phase Ib clinical trial in '
                        'patients with advanced or refractory solid tumors; '
                        'and BGB-3245, an investigational oral selective small '
                        'molecule inhibitor of monomeric and dimeric forms of '
                        'activating BRAF mutations, which is in Phase I '
                        'clinical trial. SpringWorks Therapeutics, Inc. has '
                        'collaborations with BeiGene, Ltd., GlaxoSmithKline '
                        'LLC, and Allogene to develop combination approaches '
                        'with nirogacestat and mirdametinib, as well as '
                        'medicines; and license agreements with Pfizer Inc. '
                        'for nirogacestat and mirdametinib. SpringWorks '
                        'Therapeutics, Inc. was founded in 2017 and is '
                        'headquartered in Stamford, Connecticut.',
 'longName': 'SpringWorks Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1571603712,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_610391524',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -62191000,
 'nextFiscalYearEnd': 1640908800,
 'open': 36.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '203 883 9490',
 'previousClose': 36.86,
 'priceHint': 2,
 'priceToBook': 4.6834145,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 37.46,
 'regularMarketDayLow': 36.04,
 'regularMarketOpen': 36.75,
 'regularMarketPreviousClose': 36.86,
 'regularMarketPrice': 36.75,
 'regularMarketVolume': 118764,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 43001400,
 'sharesPercentSharesOut': 0.0496,
 'sharesShort': 2131988,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1645473,
 'shortName': 'SpringWorks Therapeutics, Inc.',
 'shortPercentOfFloat': 0.2245,
 'shortRatio': 7.13,
 'startDate': None,
 'state': 'CT',
 'strikePrice': None,
 'symbol': 'SWTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -13.84,
 'twoHundredDayAverage': 34.603165,
 'volume': 118764,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.springworkstx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '06902'}